Compare ImmunityBio Inc. Common Stock (IBRX) vs National Energy Services Reunited Corp Ordinary Shares (NESR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs National Energy Services Reunited Corp Ordinary Shares — how do they compare? ImmunityBio Inc. Common Stock trades at $10.1 (market cap $10.39B), while National Energy Services Reunited Corp Ordinary Shares trades at $19.71 (market cap $2.12B). The key difference: ImmunityBio Inc. Common Stock is far larger — about 4.9× National Energy Services Reunited Corp Ordinary Shares's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, National Energy Services Reunited Corp Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 6 Days and National Energy Services Reunited Corp Ordinary Shares for 0 Days on average.
| IBRX | NESR | |
|---|---|---|
Market Cap | $10.39B | $2.12B |
Volume | 11,509,049 | 3,257,316 |
Sector | Health | Energy |
52-Week High | $11.55 | $36.31 |
52-Week Low | $1.98 | $10.41 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.84B | $2.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About National Energy Services Reunited Corp Ordinary Shares
National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →
